NovaSOL® IMMUNE CONCEPTS


Our "IMMUNE CONCEPTS" are ready to use for private label and combine two strong proporties:

  • NovaSOL® creates a superior structure, which is very similar to the human body´s own structure (physiological micelles). This structure enhances bioavailability, being a valid efficacy claim according to claims directive 1924/2006, Enrichment Directive 1925/2006, Guideline 2002/46/EG.
  • The ingredients used in the product concepts carry solid labeling relevant EFSA claims, including their contribution to a normal functioning of the immune system, which are covered by EU Regulation 432/2012.

NovaSOL® GUMMY IMMUNE

Our "GUMMY IMMUNE" finished product concept for private label use combines three immune related ingredients in a favorable and modern gummy format: Vitamin C, Vitamin D and Zinc. These powerful sweets combine EFSA approved immune system related claims with superior potency for human health in a unique, premium and tasty manner.

Learn more about NovaSOL® GUMMY IMMUNE by downloading the brochure (PDF, 1,0 MB).

NovaSOL® DUO IMMUNE

Our "DUO IMMUNE" finished product concept for private label use combines optimized galenics for water & fat soluble ingredients in the unique Duocap® format: NovaSOL® ADEK (K1, K2) vitamins in the outer capsule + water soluble ingredients in the inner capsule. This powerful blend combines EFSA approved immune system related claims with superior potency for human health in a unique and premium manner.

Learn more about NovaSOL® DUO IMMUNE by downloading the brochure (PDF, 2,3 MB).

NovaSOL® IMMUNE M2 SHOT (available in 2021)

Our "IMMUNE M2 SHOT" finished product concept for private label use combines microbiome & mitochondria support in a premium liquid shot format. This powerful blend of micellized Coenzyme Q10 and bifidobacterium lactis HN019TM provides synergistic support of immune function in an innovative 3phase shot serving for optimal active ingredient shelf life and absorbtion.

Learn more about NovaSOL® IMMUNE M2 SHOT by downloading the brochure (PDF, 833,9 KB).